High-priced meds spur dosing debate

What's a drug worth? In the case of Cerezyme, a remedy for a rare inherited enzyme deficiency known as Gaucher disease, the answer is $300,000 a year. But experts are questioning whether lower doses of the med would work as well--besides saving some $200,000 per year per patient.

Pharma companies have faced complaints about prices for years, including accusations that they inflate the required doses to boost sales. When those drugs are super-expensive, like Cerezyme, the debate becomes highly fraught. When a study showed that a half-dose of Genentech's Avastin--which runs $100,000 a year--might be as effective in lung cancer as a full one, some doctors switched. Genentech maintains that doses were set for maximum cancer-fighting.

- read the New York Times article

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.

Patients with epithelioid sarcoma previously had no targeted treatment options, but that'll change with Epizyme's approval for Tazverik.